Condition: Breast Cancer · Trop2 · PET/CT · Sponsor: The First Affiliated Hospital of Xiamen University
To evaluate whether serial 68Ga-MY6349 PET/CT imaging can serve as a noninvasive biomarker to predict the therapeutic efficacy of Trop2-targeted antibody-drug conjugate (Trop2-ADC) therapy in breast cancer patients.
This description comes directly from the study's public registry record.
Liang Zhao, phd · 86 18818350620 · wzhaoliang01@163.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Xiamen University | Xiamen, Fujian, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07046689